Bionano Genomics, Inc. Annual Report: How They Did This Year (Ending December 31, 2025)

Hey there! Let's break down how Bionano Genomics has been doing, based on their report for the year ending December 31, 2025. This past year, they've been active in several areas. They focused on funding, internal changes, and technology wins.

For the year ending December 31, 2025, Bionano's total sales were $35.0 million. This was a 4.1% drop from $36.5 million in 2024. Even with cost-cutting, the company lost $100.0 million in 2025. This was better than their $115.0 million loss in 2024. By December 31, 2025, Bionano had $25.0 million in cash. This was a big drop from $60.0 million at the end of 2024. They used $80.0 million for operations during 2025.

How They're Funding Themselves

Bionano has been busy raising money to operate and grow. Here's a look at how they've been doing it:

• Borrowing with a Twist (Convertible Debt): They've used different types of "convertible debt." This means they borrowed money, but lenders can turn that debt into company stock later. It's a common way for growing companies to get cash. It can avoid immediately issuing more shares, but might mean more shares later. They had several deals. This included $25.0 million in "Senior Secured Convertible Notes Due 2025," which they repaid or converted. They also made deals with "High-Trail" for up to $20.0 million in extra convertible debt. These deals offer flexibility and aim to limit immediate share dilution.
• Selling New Shares (Stock Offerings): They also sold new shares to investors through "Registered Direct Offerings." These often include "warrants," which are like coupons. Warrants give investors the right to buy more shares later at a set price. They completed several offerings in 2024 and early 2025. This raised about $40.0 million in 2025 alone. For example, in February 2025, an offering raised $15.0 million. They sold 4.5 million shares at $3.33 per share. It also included warrants to buy another 4.5 million shares at $4.00 per share. As of March 19, 2026, about 11.09 million shares were outstanding. These offerings can increase total shares. This means your ownership percentage could get smaller (this is called dilution).

Operational Adjustments

• Workforce Reductions: Bionano made tough choices, cutting about 20% of its staff in 2024. Further cuts in early 2025 aimed for $15.0 million in yearly cost savings. Companies often do this to cut operating costs and become more efficient. It can signal financial strain, but also helps streamline operations. They plan more cost-saving efforts.

Where They Make Their Money & Company Structure

Bionano aims to "transform how the world sees the genome." They use optical genome mapping (OGM) solutions, DNA/RNA purification systems, diagnostic services, and software. They are shifting from just an instrument company to offering a full range of genomic solutions.

The Big Picture: Their Market Opportunity

Bionano sees a huge, growing market for genomics products and services. They estimate the global market will hit about $85.1 billion by 2030. This is a big jump from roughly $44.5 billion in 2024. That's a 12.6% compound annual growth rate (CAGR)!

For their OGM technology, they see about $10.0 billion in yearly economic potential. This includes:

• Cytogenetics and Molecular Pathology: They estimate 10,000 cytogenetic labs globally (excluding India and developing countries) analyze 10.0 million samples yearly.
• Cell and Gene Therapy: About 1,400 pharma and biotech companies work on cell therapies. This area alone could add $3.0 billion yearly to the OGM market, with 2.4 million potential samples per year.
• Software: Their software (like VIA) works with any platform. It also taps into the clinical Next-Generation Sequencing (NGS) market. This market was about $4.1 billion in 2025. It should grow to $8.2 billion by 2029, an 18.8% CAGR.

They also see future OGM opportunities. These include newborn screening, population genomics, and neurological/cardiological risk assessment.

How They Make Their Products

Bionano largely outsources instrument, reagent (test chemicals), and chip manufacturing. They rely on other companies to build these parts. However, they handle quality control for all outsourced products. They also do final assembly and quality control of their chips in-house.

• Instruments: They sell core machines like "Saphyr and Stratys Instruments" for genomic analysis. These systems find structural changes in chromosomes. This is vital for understanding genetic diseases and cancer. By December 31, 2025, 387 OGM systems were installed globally. This was a 4.3% increase from 371 systems in 2024. It shows more labs use their core technology.
  • What makes them special? Bionano believes Saphyr and Stratys systems are most sensitive. They detect structural variations (DNA changes larger than 500 base pairs). They are also cost-effective. Consumables cost about $500 per genome, often cheaper than other methods. Plus, they are fast and scalable. They show up to a 75% faster turnaround time for some blood cancer analysis versus older methods.
  • Key Applications: OGM is seeing demand in two main areas:
    • Consolidating traditional cytogenetics: This replaces older, complex methods for finding structural variations. This includes constitutional genetic disorders (like inherited conditions, 1.7 million samples yearly) and cancer (especially blood cancers, 8.3 million samples yearly). OGM offers a single, complete tool for these analyses.
    • Cell and Gene Therapy: OGM ensures new genomic changes in cell and gene therapies don't accidentally add harmful structural variations. This is a key quality control step in this new field.
  • Saphyr vs. Stratys: The Saphyr instrument analyzes up to 4,000 human genomes yearly. The newer Stratys system (placed with customers since late 2022) handles up to 13,500 human genomes yearly. This offers about 4 times the throughput of Saphyr. Saphyr images DNA at about 205 Gbp per hour. Stratys images between 530 and 820 Gbp per hour.
• Consumables: These are the supplies customers regularly need for their instruments, like reagents and kits. This is often key to a biotech company's sales model, like how printer companies profit from ink. For the year ending December 31, 2025, they sold 30,171 flowcells. These are chips used to process OGM samples. This was a slight 0.4% decrease from 30,307 flowcells sold in 2024. The installed base grew, but consumable usage dipped slightly.
  • The Chips: They sell Saphyr and Stratys Chips. These have tiny "nanochannels" that linearize DNA for imaging. They make these chips like semiconductors. This makes them cheap to produce and highly scalable.
  • Prep Kits: Their Bionano Prep™ and DNA labeling kits (like DLS) are essential for preparing DNA samples. These kits gently extract very long DNA strands (UHMW DNA). They then attach fluorescent labels to specific DNA parts, which instruments "read."
• Software: They also earn money from software like "VIA." It helps analyze instrument data and integrates other genomic tech data. Their long-term software goal is to make OGM widespread. They simplify data interpretation and integrate other genomic data (like NGS and array tech). This provides the most complete genome analysis. They believe their software is unique. It's the first to fully integrate OGM structural variation (SV) analysis. It combines this with data from NGS and microarray tech.
  • BioDiscovery's Role: Acquiring BioDiscovery helped them expand software. It interprets data across NGS, CMA, and OGM, making OGM easier to adopt.
  • Monetization Strategy: For NGS and array tech customers, Bionano offers VIA software "pay-per-sample." This lets them join the wider genomics market. It could also encourage these customers to adopt OGM later, expanding their software network.
• DNA/RNA Purification: They sell the "Ionic® Purification system." It extracts and purifies high-quality DNA or RNA from various samples. This is a key first step for OGM. Their tech works best with very long DNA strands (UHMW DNA).
  • Ionic's Advantage: The Ionic system isolates enough OGM DNA from fewer cells. Traditional methods need 1.5 million cells. Ionic provides purer, undamaged DNA. This makes OGM work more efficiently. While mainly supporting OGM, Ionic also has customers for general nucleic acid purification. Bionano plans to keep supporting and growing this.
• Diagnostic Services: Their Bionano Laboratories business offers specialized testing. Their San Diego lab is certified (CLIA and CAP) and performs OGM testing. They offer an OGM test for FSHD1 muscular dystrophy. They also provide OGM testing for research to other groups. In 2024, they stopped offering non-OGM tests. In 2025, they stopped OGM tests for blood cancers and pre/post-natal genetic disorders. Their diagnostic services are now more focused.
  • Strategic Role: Bionano Laboratories develops new OGM tests. They also work with insurers to get reimbursement. If successful, they will share strategies with other labs. This could boost OGM system demand. They also let labs without a system still access OGM testing. They are even exploring OGM for conditions like Fragile X syndrome.
• Global Reach: Their sales are global. They earn money from the Americas, EMEA, and Asia Pacific. However, their research and development is mostly in the U.S.
• Subsidiaries: Bionano operates through wholly owned subsidiaries. These include Lineagen (Bionano Laboratories), BioDiscovery, and Purigen Biosystems, Inc. These acquisitions expanded them into clinical testing, software, and nucleic acid isolation. This created an "end-to-end" solution for customers.

Their Strategy Going Forward

Bionano focuses on increasing OGM system adoption. Their goal: make it easier to find structural variations. This enables new research to better understand their role in human health. Their strategy includes:

• Proving OGM is Superior: They want to show OGM systems are better than older techniques. This applies to constitutional genetic disorders and blood cancers. They highlight OGM's superior sensitivity, better success, faster results, and lower costs. They aim to "digitize" old microscope techniques.
• Accelerating Reimbursement & Standard of Care: They work hard to get OGM covered by insurance. They also seek "Standard of Care" (SOC) recognition from medical societies. They once invested in three multi-center clinical studies. These led to four publications. However, they are no longer funding these specific programs. Instead, they use existing evidence to push for reimbursement.
• Supporting Scientific Publications: They actively encourage customers to publish OGM research. Over 1,800 papers now show OGM advancements. More than 75% published since 2021, and 24% appeared in 2025 alone. These publications validate the technology. They show its impact on critical medical needs.
• Continuous Innovation: They plan to keep improving products and technology. This means hardware upgrades, new consumables, and regular software updates for customers. The idea: make OGM systems easier to use. Boost throughput, sensitivity, and accuracy of existing systems. Customers won't need to buy new instruments.
• Partnering for Clinical Adoption: They plan more customer collaborations for validating studies. They will partner with clinical diagnostic companies. This will commercialize lab-developed tests (LDTs) in the U.S. and globally.
• Complementing NGS: They believe combining OGM with NGS offers the most complete, cost-effective way. It analyzes all types of genome variations. NGS handles very small changes (under 500 base pairs). OGM fills the gap, detecting structural variations over 500 base pairs. This solves cases NGS alone cannot.
• Focus on Existing Customers: Going forward, they will focus less on selling new OGM systems. Instead, they will maximize usage by existing customers.

Recent Wins & Progress (Good News!)

Despite financial challenges, Bionano hit important milestones in 2025. These could help their business long-term:

• Software Upgrades: They upgraded their "VIA" and "Solve™" software. This makes genomic data analysis easier, faster, and more accurate.
• Key Reimbursement Code: The AMA created a second "Category I CPT code" for OGM. This code (81354) is for constitutional genetic disorders. A CPT code is a standard billing code. Doctors and labs use it to get paid by insurers. A Category I code is a big deal. It makes OGM reimbursement much easier. This can significantly boost adoption and sales. The CLFS priced this new code. It became effective January 1, 2026.
• Increased Payment from Medicare/Medicaid: CMS set a payment rate for the new CPT code (constitutional genetic disorders). They also increased the rate for the existing OGM CPT code (81195) for blood cancers. This increase, effective January 1, 2026, is a significant 47% jump from 2025. This is great news for potential sales from these tests.
• Strong Scientific Validation: The scientific community continues to validate OGM's usefulness. In 2025, they highlighted their tech's effectiveness. This was done through nine studies at the ASHG Meeting. Multiple publications also showed OGM's use for cancer biomarkers. It also overcomes other tech limitations in acute leukemia. A key highlight was a publication. It described the largest single-institution study of OGM's clinical use across blood cancers. Overall, 450 peer-reviewed publications in 2025 showed OGM's growing acceptance and use. In total, customers published over 1,800 OGM papers. More than 75% came since 2021, and 24% appeared in 2025 alone.

What We Know About Their Size

As of June 30, 2025, regular investors (non-affiliates) held about $12.15 million in common stock. Each share was priced at about $3.28. This implies about 3.7 million non-affiliate shares were outstanding. Total shares outstanding were 11.09 million as of March 19, 2026. This, plus their "smaller reporting company" status, shows Bionano is still a small public company. This can mean higher growth potential, but also higher risk.

Key Risks to Keep in Mind (Very Important!)

This report highlights significant risks for investors:

• Can They Keep Going? (Going Concern Risk): This is a big risk, and the company has stated it strongly. They have recurring losses and negative cash flow. This creates substantial doubt about their ability to operate for the next 12 months. By December 31, 2025, they had only $25.0 million in cash. They used $80.0 million for operations during the year. They urgently need to raise more money very soon. If they can't, they might cut operations further, sell assets, or even shut down completely. In that case, investors might lose their entire investment.
• Need for Profitability: They have a history of losses, including a $100.0 million loss in 2025. They need to improve profit margins, extend their cash runway, and find a clear path to profit.
• Limited Commercial History & Fluctuating Results: As an early-stage company, predicting future performance is hard. Their quarterly and annual results have fluctuated. They will likely continue to do so, making their stock price volatile.
• Dependence on Single Suppliers and Manufacturers: Bionano relies on a single manufacturer to produce and test its instruments. This manufacturer isn't obligated to produce instruments without a purchase order. They also don't hold extra inventory. Bionano could face delays or supply issues if demand spikes or the manufacturer has problems. Many OGM and ITP (DNA/RNA purification) reagents come from limited suppliers. Some are single-source. Bionano believes alternatives exist. However, finding and validating new suppliers would take significant time. This could disrupt their ability to provide testing kits. This heavy reliance on single sources for critical parts and manufacturing is a big risk. It threatens their operations and ability to meet customer demand.
• Customer Concentration: In 2024, 15% of their total sales came from just "One Customer." This is a big risk. If that customer reduces orders or stops buying, it could greatly impact the company's sales and financial health. It's like putting too many eggs in one basket.
• Dependence on Research Spending: Their sales depend heavily on research spending. This includes clinical labs, academic institutions, and drug companies. If that spending goes down, demand for Bionano's products could drop.
• Challenges with New Products: Successfully developing and launching new products is crucial. If not managed well, financial results could suffer.
• Market Size & Acceptance: Their estimated market might be smaller than expected. New markets might also grow slower than hoped, limiting sales. If their products don't gain market acceptance, their sales will suffer.
• Research Use Only (RUO) Limitations & Regulatory Hurdles: Many products are currently "research use only" (RUO). This limits their use. For example, Bionano sells RUO OGM systems to certified clinical testing labs. These labs might use Bionano's systems to develop "Laboratory Developed Tests" (LDTs) for patient diagnosis. Historically, the FDA took a hands-off approach to regulating LDTs. However, on May 6, 2024, the FDA published a new rule. It would have phased out this approach over four years. LDTs would have faced stricter rules, needing FDA approval before sale. This could have been a big hurdle for Bionano's customers and business. Good news: In March 2025, a U.S. District Court canceled this rule. This stopped its implementation. For now, stricter LDT regulations are not moving forward. However, the FDA might try similar rules later. If so, or if Bionano wants to market RUO products for clinical use, they'd need expensive, time-consuming, uncertain approvals. They also face strict, evolving data privacy and security laws. For Bionano Laboratories, this means complying with HIPAA. If they fail to protect this data or report breaches on time, they could face big fines and legal trouble. This could hurt their business.
• Uncertainty in Healthcare Policy: Healthcare rules and how companies like Bionano get paid are always changing. For example, the Affordable Care Act (ACA) affects health insurance. It has faced past legal challenges and might again. Also, the 2022 Inflation Reduction Act extends health insurance subsidies. This impacts coverage and reimbursement. It's unclear how these or future legislative changes might affect Bionano's business. This includes their ability to get diagnostic tests covered and reimbursed. This creates uncertainty for their sales.
• Intellectual Property Risks: Protecting their patents and intellectual property is vital. If they can't, competitors could gain an advantage. Some IP comes from government programs. This means the government has rights (like "march-in" rights). These could limit Bionano's exclusive control. They also rely on licenses from others, and losing those rights could harm them.
• Debt Restrictions: Their "Debentures" (a type of loan) and related agreements restrict current and future operations. If they default on these loans, they might not be able to make required payments.
• Integrating Acquisitions: They acquired companies (Lineagen, BioDiscovery, Purigen). Successfully combining these businesses and realizing benefits can be challenging.
• Competition: The genomics industry is very competitive. New tech or rival improvements could impact Bionano's market.
• Macroeconomic Headwinds: Broader economic issues could negatively affect their business. These include inflation, supply chain problems, bank failures, and global conflicts. Suppliers and customers could also be affected.
• Attracting and Retaining Talent: As a tech company, keeping key scientists and management is crucial for innovation and success.
• Nasdaq Listing Risk: If they don't meet Nasdaq Capital Market requirements, their stock could be delisted. This makes it harder for investors to trade.
• Potential Dissolution and Liquidation: This is the most severe risk. If they can't raise enough money, their board might decide to dissolve and liquidate the company. In that case, cash for stockholders would depend on timing. It also depends on how much money is set aside for debts and liabilities.

This guide offers a snapshot of Bionano Genomics' performance, strategy, and risks for the year ending December 31, 2025. It highlights their financial situation, market opportunities, product developments, and the significant challenges they face, especially regarding their ability to continue operations. For a comprehensive understanding, investors should always review the company's official filings and conduct their own thorough due diligence before making any investment decisions.